Clinical Trials Logo

Filter by:
NCT ID: NCT01587664 Terminated - Clinical trials for Swallowing Disorders

NewBreez Safety and Efficacy Evaluation

Start date: May 2012
Phase: N/A
Study type: Interventional

The objective of this clinical study is to evaluate the safety and efficacy of the NewBreez intra-laryngeal implant in patients with dysfunctional larynx.

NCT ID: NCT01587053 Terminated - Clinical trials for Cardio-vascular Diseases

Anti Vitamin K Therapeutic Education

Start date: April 2012
Phase:
Study type: Observational

The purpose of this study is to measure the INR (International Normalized Ratio) time percentage in the target zone (TTR: time in therapeutic range) of children benefiting from the AVK therapeutic education program.

NCT ID: NCT01586728 Terminated - Cystic Fibrosis Clinical Trials

Oxygen Therapy in Cystic Fibrosis

MUCOXY
Start date: October 2012
Phase: N/A
Study type: Interventional

This is an open, multicenter, prospective, randomised and cross over study, comparing in patients with cystic fibrosis aged > 6 years, 2 periods of 6 weeks of oxygen therapy or room air, separated by a wash out period of 2 to 6 weeks.

NCT ID: NCT01584245 Terminated - Cow's Milk Allergy Clinical Trials

Evaluation of the Efficacy of an Amino Acid Based Formula in Infants

Start date: February 2012
Phase: N/A
Study type: Interventional

This clinical trial will evaluate the efficacy of an amino acid formula in infants with allergic manifestations.

NCT ID: NCT01583114 Terminated - Clinical trials for Dilated Cardiomyopathy

PREclinical Mutation CARriers From Families With DIlated Cardiomyopathy and ACE Inhibitors

PRECARDIA
Start date: December 2011
Phase: Phase 3
Study type: Interventional

This is a multicentre European double-blind,randomized and controlled trial with 2 parallel groups (1 study medication, 1 placebo) in order to analyse the impact of ACE inhibitors (ACEi) in subjects who carry a mutation but have not yet developed DCM (dilated cardiomyopathy). Objective of the trial: Study the impact of ACE inhibitors (ACEi) in subjects who carry a mutation (leading to a genetic form of heart failure) but have not yet developed DCM. Context. Dilated Cardiomyopathy (DCM) is one of the leading causes of Heart Failure due to systolic dysfunction and at least 30% of DCM are of familial/genetic origin, usually with autosomal dominant inheritance, and underlying genes and mutations are increasingly identified. Familial Dilated Cardiomyopathy (fDCM) is characterized by age-related penetrance (or delayed-onset), that means that the cardiac expression of the disease (echocardiographic abnormalities) is usually absent for a long period and progressively appears with advanced age, usually after 20 years of age Hypothesis : ACEi may delay or prevent the occurrence of DCM in these subjects (pre-clinical stage). Expected results: If the hypothesis is confirmed, and as a consequence, the knowledge derived from basic research (genes identification in DCM) will be translated into clinical practice (early identification of subjects at high risk of developing heart failure through predictive genetic testing) with the development of new therapeutic management (early ACEi) that will help to decrease the morbidity and mortality associated with the disease. This will constitute a paradigm of the development of preventive medicine thanks to the development of genetics in the cardiovascular field. Subjects who are concerned are ≥18 years of age and ≤60 years, carry a mutation responsible for DCM and are at a preclinical stage of the disease. Total duration of treatment (perindopril versus placebo) is 3 years. A total number of 200 participants will be enrolled (100 in each group) in 7 centres.

NCT ID: NCT01583088 Terminated - Clinical trials for Amyotrophic Lateral Sclerosis

Early Stage Amyotrophic Lateral Sclerosis Phrenic Stimulation

RespiStimALS
Start date: September 2012
Phase: Phase 3
Study type: Interventional

ALS is is characterized by a progressive degeneration of motor neurons, leading to progressive weakness of muscles, including respiratory muscles, the diaphragm. Although specific therapy is lacking, correct respiratory therapy improves quality of life and increases survival. Substituting the failing respiratory muscles by non invasive mechanical ventilatory assistance (NIV) is the current standard of care. Intradiaphragmatic phrenic nerve stimulation is a new treatment and has been the object of a preliminary international proof-of-concept multicenter trial. This trial suggests that the intradiaphragmatic phrenic nerve stimulation slows down the rate of decline of the diaphragm. Our new hypothesis is that phrenic stimulation induces diaphragm conditioning and can delay the need for mechanical ventilation in ALS patients. We will study, during 24 months, 2 groups of 37 patients at the beginning of the respiratory dysfunction, using a intradiaphragmatic phrenic nerve stimulation in one group and a sham stimulation in the other group. Although, all the patients will be implanted, thus, at the end of the study, all the patients will receive effective stimulation.

NCT ID: NCT01582646 Terminated - Clinical trials for Postthoracotomy Pain

Analgesic Effect of Beta 2-mimetics in the Treatment of Neuropathic Pain

Bêtapain
Start date: January 2012
Phase: Phase 2
Study type: Interventional

Neuropathic pain is due to a lesion or disease affecting the nervous system. Antidepressants (ADs) are recommended as the first line treatment. In a murine model, the investigators evidenced that antidepressants antiallodynic action is mediated through β2-adrenergic receptor stimulation and that β-mimetics display the same effect. These data support the idea that β-mimetics could offer a therapeutic alternative to ADs for neuropathic pain treatment. This study will aim at assessing the effects of terbutaline on neuropathic pain symptoms.

NCT ID: NCT01579864 Terminated - Anesthesia Clinical Trials

Succinylcholine or Rocuronium for Rigid Bronchoscopy Under General Anesthesia

Broncho-SR
Start date: January 2012
Phase: Phase 4
Study type: Interventional

Myorelaxation is generally used as a part of general anesthesia for interventional rigid bronchoscopy. Succinylcholine is most often used because its short duration of action but rocuronium can be used since sugammadex permits a rapid and complete reversal of the neuromuscular block. The aim of ths study is to compare both agents.

NCT ID: NCT01577576 Terminated - Clinical trials for Monckeberg Medial Calcific Sclerosis

Mechanical Stress Effects on the Cardiovascular Adaptations of Peripheral Arterial Calcifications Among Athletes

MediaSport
Start date: September 2012
Phase: N/A
Study type: Observational

The main objective of this study is to obtain data for the integrated analysis of morphological, functional and biomechanical parameters pertaining to lower limb arteries in various categories of elite athletes (without cardiovascular risk and practicing high- or low-impact aerobic activities which preferentially implicate lower limb activity) as compared to (each other and to) sedentary controls.

NCT ID: NCT01573988 Terminated - Volunteers Clinical Trials

Satiety, Meal Frequency and Nutritional Aspects

SAFRAN
Start date: August 2010
Phase: N/A
Study type: Interventional

In this study, the investigators are interested in assessing the effects of the isocaloric increase of eating frequency on appetite and metabolism. How the consumption of an isocaloric breakfast in four intakes vs. one can modify satiety and appetite control in lean and obese subjects through : - the physiological consequences : difference in postprandial kinetics of glucose, non esterified fatty acid, triglyceride, the secretion of satiety gut hormone (insulin, ghrelin, leptin and cholescystokinine (CCK), peptide YY (PYY), glucagon-like peptide-1 (GLP-1), nutrients oxidative fate and plasmatic oxidative stress (Malondialdehyde (MDA), glutathion, lipid hydroperoxides) - eating behavior during an ad libitum buffet test meal